Related by context. All words. (Click for frequent words.) 86 randomized controlled trials 85 randomized clinical trials 78 meta analyzes 76 RCTs 76 randomized controlled clinical trials 75 placebo controlled trials 75 observational studies 74 randomized controlled trial 73 meta analysis 73 placebo controlled studies 73 randomized clinical 69 randomized controlled 69 multicenter trials 68 randomized controlled trials RCTs 68 subgroup analyzes 68 prospective randomized 67 epidemiological studies 67 trials RCTs 66 multicenter study 66 observational study 65 epidemiologic studies 65 nonrandomized 65 longitudinal studies 65 randomized 65 multicenter 64 placebo controlled clinical trials 64 placebo controlled clinical 63 clinical trials 63 placebo controlled 63 chemoradiotherapy 63 prospective randomized controlled 62 randomized placebo controlled 62 liver transplant recipients 62 clinical trial 62 lipid lowering therapy 62 statin therapy 62 randomized controlled clinical 62 randomized Phase III 62 Randomized trials 62 vitamin D supplementation 62 Subgroup analyzes 61 UKPDS 61 VADT 61 multicenter randomized 61 active comparator 61 prospective observational 61 ALLHAT 61 prospective cohort 61 nesiritide 61 RE LY 61 adjuvant therapy 61 HCV SPRINT 61 prospective longitudinal 61 multicentre 61 double blinded randomized 61 randomized blinded 61 Meta analyzes 60 paclitaxel eluting stents 60 DAPT 60 prospective observational studies 60 randomized multicenter trial 60 multicentre study 60 retrospective cohort 60 metaanalysis 60 hypertensive patients 60 adjuvant chemotherapy 60 rosuvastatin 60 neoadjuvant 60 subanalysis 60 statins 60 BARI 2D 60 antiplatelet therapy 59 beta blocker therapy 59 randomized multicenter 59 chemoradiation 59 Observational studies 59 mycophenolate mofetil 59 ticagrelor 59 SCD HeFT 59 phase IIIb 59 antihypertensive medications 59 retrospective cohort study 59 IMPROVE HF 59 prospective randomized placebo 59 MERLIN TIMI 59 olaparib 59 HORIZONS AMI trial 59 adalimumab 59 topical NSAIDs 59 riociguat 59 MADIT II 59 multicentre randomized 59 RE LY ® 59 antioxidant supplements 59 adjuvant therapies 59 SPIRIT III 59 efficacy 59 antihypertensive therapy 58 dose regimens 58 CALGB 58 selenium supplementation 58 antihypertensive drugs 58 fluvastatin 58 NSABP B 58 studies 58 drug eluting stents 58 ConclusionThis 58 adjuvant radiotherapy 58 antiplatelet drugs 58 metastatic RCC 58 NICE SUGAR 58 warfarin therapy 58 sentinel node biopsy 58 Phase III trials 58 HAART regimens 58 eprotirome 58 teriflunomide 58 double blinded placebo 58 substudy 58 thromboprophylaxis 58 calcium supplementation 58 multicenter prospective 58 antithrombotic therapy 58 glatiramer acetate 58 androgen suppression 58 dose escalation 58 Edge STudy 57 blinded randomized controlled 57 MADIT CRT trial 57 NO# [002] 57 EVEREST II 57 GnRH agonists 57 bendamustine 57 Carotid Revascularization Endarterectomy vs. 57 SPIRIT IV 57 ONTARGET 57 prognostic factors 57 AVERROES 57 confirmatory clinical 57 ATACAND 57 statin 57 tiotropium 57 RE LY trial 57 lymphadenectomy 57 revascularization procedures 57 cardiovascular morbidity 57 eptifibatide 57 carotid artery stenting 57 phase IIa 57 postmenopausal women 57 IMPROVE IT 57 Stenting Trial CREST 57 dabigatran etexilate 57 Cochrane Systematic Review 57 fondaparinux 57 double blind placebo 57 inhaled corticosteroids 57 nonrandomized studies 57 candesartan 57 SABCS 57 dosage regimens 57 CARE HF 57 HYVET 57 generalizability 57 FOLPI 57 placebo controlled Phase 57 tamoxifen therapy 57 RTOG 57 thiazide diuretics 57 NATRECOR ® 57 sunitinib 57 placebo controlled Phase III 57 levosimendan 57 APPRAISE 57 preoperative chemotherapy 57 Cholesterol Levels SPARCL 57 Cochrane reviewers 57 antioxidant supplementation 57 antiplatelet agents 57 CAMMS# 56 ExTRACT TIMI 56 MADIT CRT 56 Phase 2b study 56 Clinical Antipsychotic Trials 56 rosiglitazone 56 testosterone supplementation 56 prospective multicenter 56 hemodialysis patients 56 pioglitazone 56 DCCT 56 chemotherapeutic regimens 56 F FDG PET 56 liver biopsies 56 β blockers 56 sorafenib Nexavar 56 phase IIb 56 PROSTVAC TM 56 multicenter placebo controlled 56 vitro studies 56 placebo controlled randomized 56 SYNTAX trial 56 pharmacological interventions 56 Digital Mammographic Imaging 56 aldosterone antagonist 56 HeFT 56 HIVNET 56 NCCTG N# 56 ACUITY trial 56 IQWiG 56 Clinical trials 56 pharmacokinetic studies 56 oncologic outcomes 56 TAXUS VI 56 NEJM 56 AIM HIGH 56 bronchial thermoplasty 56 tolvaptan 56 clinically meaningful 56 infantile colic 56 randomized double 56 statin medications 56 ximelagatran 56 tocilizumab 56 aldosterone antagonists 56 thrombolytic therapy 56 noninferiority 56 multicenter clinical 56 afatinib 56 phase IIa clinical 56 SPARCL 56 PRECiSE 56 nephron sparing surgery 56 lymph node dissection 56 dosing regimens 56 cilostazol 56 neoadjuvant treatment 56 Prostate Cancer Prevention 56 prospective observational cohort 56 FDG PET 56 DSMB 56 paricalcitol 56 blind randomized 56 viral kinetic 56 ACCORD Lipid 56 TAXUS ATLAS 56 rFVIIa 56 NATRECOR R 56 radical nephrectomy 56 clinical pharmacology studies 56 RRMS patients 56 antiplatelet therapies 56 ARCOXIA 56 PLCO 55 antiepileptics 55 multicenter Phase II 55 ECASS 55 chemoprevention trials 55 antibiotic regimens 55 prospective nonrandomized 55 postoperative chemotherapy 55 Randomized controlled 55 multicenter randomized controlled 55 renal tumors 55 antihypertensive agents 55 antibiotic prophylaxis 55 Randomized clinical trials 55 abatacept 55 ELCAP 55 conventional angiography 55 APTIVUS 55 ASCEND HF 55 phase IIb clinical 55 glitazones 55 phase IIb trial 55 Phase IIIb study 55 ENDEAVOR IV 55 bevacizumab 55 heartwire 55 psychotherapies 55 SORT OUT III 55 dual antiplatelet therapy 55 vicriviroc 55 Val HeFT 55 carotid stenting 55 Doxil ® 55 coronary revascularization 55 heavily pretreated patients 55 BCIRG 55 oral bisphosphonates 55 recurrent GBM 55 pazopanib 55 WHEL 55 neratinib 55 Xelox 55 oral Xeloda 55 randomized multicenter Phase III 55 anastrozole 55 deferiprone 55 TAXUS IV 55 folate supplementation 55 Phase 2a trial 55 Aggressive Reduction 55 CYPHER Stent 55 PRoFESS 55 prospective randomized multicenter 55 multicenter randomized clinical 55 cediranib 55 psychodynamic psychotherapy 55 postmarketing surveillance 55 TAXUS Liberte Stent 55 KRAS variant 55 canakinumab 55 insulin glargine 55 glucose lowering 55 vertebroplasty 55 phase Ib 55 celecoxib 55 randomized Phase IIb 55 NNRTI resistance 55 tipranavir 55 darunavir ritonavir 55 oral anticoagulation 55 endarterectomy 55 methodological limitations 55 dosing cohorts 55 bevacizumab Avastin 55 letrozole 55 Kaplan Meier analysis 55 antitumor effect 55 oral diclofenac 55 prospectively defined 55 observational cohort 55 coronary interventions 55 rt PA 55 lipid lowering agents 55 NSTE ACS 55 PROactive study 55 pre menopausal 55 Protelos 55 HCV RESPOND 2 55 oral rivaroxaban 55 multicenter clinical trials 55 EURIDIS 55 Phase IIb trial 55 AIR2 Trial 55 patients undergoing percutaneous 55 temsirolimus 55 pegylated interferon alfa 2b 55 pelvic lymphadenectomy 55 nulliparous women 54 inhaled steroids 54 lipid lowering drugs 54 longitudinal cohort study 54 direct thrombin inhibitors 54 Randomized Clinical Trial 54 stage IIIB 54 RoACTEMRA 54 CLBP 54 CYPHER R Sirolimus eluting 54 immunosuppressive regimens 54 oral FTY# 54 intravesical therapy 54 tibolone 54 Phase #/#a 54 macrovascular disease 54 allopurinol 54 neoadjuvant chemotherapy 54 pegylated liposomal doxorubicin 54 radiographic outcomes 54 adjuvant radiation 54 tolerability 54 lacosamide 54 nab paclitaxel 54 BoNTA 54 blind randomized placebo 54 ACTEMRA TM 54 SGAs 54 dose cohorts 54 coronary angiography 54 HIV HCV coinfected 54 Health Initiative WHI 54 monotherapy 54 viral kinetics 54 LUX Lung 54 PREZISTA r 54 radical cystectomy 54 Mylotarg 54 prospectively randomized 54 BOLDER II 54 strontium ranelate 54 symptomatic VTE 54 COPAXONE R 54 androgen deprivation 54 stable angina 54 iniparib 54 transcatheter aortic valve implantation 54 CYPHER ® Stent 54 multicenter phase 54 ENDEAVOR clinical 54 ivabradine 54 prucalopride 54 dosing schedules 54 colorectal liver metastases 54 elevated CRP 54 rivaroxaban 54 #F FDG PET 54 superficial bladder cancer 54 chest radiographs 54 Screening Trial DMIST 54 peg interferon 54 pyridostigmine 54 APTIVUS r 54 angiotensin receptor blockers 54 XELOX 54 nondiabetic patients 54 sunitinib malate 54 ADAGIO study 54 therapeutic regimens 54 longitudinal study 54 intensive statin therapy 54 homocysteine lowering 54 ACOSOG Z# 54 epidemiologic 54 invasive coronary angiography 54 Epidemiologic studies 54 Afatinib 54 Phase 1b trial 54 retrospective observational study 54 Intervention Effectiveness 54 valsartan 54 Subgroup analysis 54 zoledronic acid 54 singleton pregnancies 54 idraparinux 54 perioperative mortality 54 meta analytic 54 pharmacologic treatments 54 coronary intervention 54 antithrombotic agents 54 liver biopsy 54 ADVANCE PD 54 adjuvant tamoxifen 54 Observational Study 54 phosphate binders 54 meta analysis pooling 54 atazanavir 54 CANCIDAS 54 premenopausal women 54 prospective multicenter study 54 post hoc 54 chromium supplementation 54 unblinded 54 Phase Ib clinical 54 folic acid supplementation 54 partial nephrectomy 54 INTERHEART study 54 elective PCI 54 neuropsychiatric symptoms 54 postmenopausal hormone therapy 54 protease inhibitor PI 54 lamotrigine 54 NEVO ™ 54 DMARD 54 Phase III randomized 54 NSAIDs 54 efficacy endpoints 54 Betaferon ® 54 CYPHER R Stent 54 atorvastatin Lipitor 54 Hydroxyurea 54 LDL lowering 53 ABSORB trial 53 thiazolidinediones 53 peginterferon 53 cystectomy 53 FOSRENOL R 53 Phase IIb 53 VTE prophylaxis 53 dose statin therapy 53 analgesic efficacy 53 Genous stent 53 renal transplantation 53 observational cohort study 53 inhaled corticosteroid therapy 53 TAXUS stent 53 axitinib 53 adenotonsillectomy 53 EORTC 53 abciximab 53 breast cancer recurrences 53 intravenous bisphosphonates 53 NSABP 53 Torisel 53 ixabepilone 53 Percutaneous Coronary Intervention 53 hydroxychloroquine 53 dose escalation Phase 53 virologic response 53 salsalate 53 non squamous NSCLC 53 micafungin 53 telcagepant 53 myocardial infarctions 53 ezetimibe simvastatin 53 carotid stents 53 zalutumumab 53 teriparatide 53 BRIM3 53 KRAS status 53 aripiprazole Abilify 53 evaluating REVLIMID 53 thoracoscopic lobectomy 53 STRIDE PD 53 hemoglobin A1c levels 53 nonpharmacologic 53 logistic regression models 53 Nesiritide 53 clevidipine 53 pioglitazone Actos 53 angiographic outcomes 53 SWOG 53 cinacalcet 53 AVAiL 53 refractory CLL 53 Clinical Outcomes Utilizing Revascularization 53 Wisconsin Sleep Cohort 53 telmisartan 53 CHAMPION PCI 53 thromboembolic events 53 eculizumab therapy 53 STEMI patients 53 PLCO trial 53 CYPHER ® Sirolimus eluting 53 ToGA 53 confounding variables 53 dietary intakes 53 Randomized 53 controlled multicenter 53 HPTN 53 ibandronate 53 ARIXTRA 53 prospective multicentre 53 nonoperative 53 valvulopathy 53 anti leukemic 53 ACC AHA 53 Phase IIB 53 VFEND 53 gemcitabine 53 GOUT 53 clopidogrel pretreatment 53 newer antipsychotics 53 antimicrobial prophylaxis 53 undergone radical prostatectomy 53 acting insulin analogues 53 ABCSG 53 visceral metastases 53 olmesartan 53 CUSTOM III 53 antiepileptic drugs 53 unfractionated heparin 53 tolerability profile 53 Candesartan 53 Intervention Trial GAIT 53 STEP BD 53 Acute Coronary Syndromes ACS 53 olanzapine LAI 53 clopidogrel Plavix 53 liver resection 53 lowering LDL cholesterol 53 OvaRex MAb 53 multicenter Phase 53 secondary efficacy endpoints 53 pneumonectomy 53 oral antidiabetic medication 53 pharmacological approaches 53 CALGB # [002] 53 methotrexate therapy 53 EchoCRT 53 glycemia 53 Allovectin 7 ® 53 paroxysmal AF 53 rosuvastatin Crestor 53 CROI 53 rEEG 53 TRITON TIMI 53 dietary modification 53 bosentan 53 chlorthalidone 53 ERSPC 53 PERSEUS 53 Prostate Lung Colorectal 53 coxibs 53 coadministration 53 intensive lipid lowering 53 sentinel lymph node biopsy 53 factorial design 53 tumor shrinkage 53 resected pancreatic cancer 53 relapsed SCLC 53 dose aspirin 53 decitabine 53 HoLEP 53 insulin detemir 53 methodologically rigorous 53 NovoTTF 53 postmenopausal 53 correlational 53 mammographic density 53 clinically localized prostate 53 Rasilez Tekturna 53 oral anticoagulants 53 Longitudinal studies 53 concomitant medications 53 dose titration 53 standard chemotherapy regimen 53 ICD therapy 53 phase IIb study 53 multicenter randomized double 53 SBRT 53 ARB telmisartan 53 CHARISMA trial 53 etanercept 53 peginterferon alfa 2a 53 adenoma recurrence 53 Adjuvant chemotherapy 53 ACCOMPLISH 53 PRIMO CABG2 53 sirolimus eluting stents 53 SLN biopsy 53 blinded randomized placebo controlled 53 metastatic HRPC 53 posaconazole 53 FOLFOX 53 multivariate analyzes 53 ACZ# 53 catheter angiography 53 PIX# [002] 53 relapsed MM 53 reboxetine 53 bioabsorbable stent 53 infliximab Remicade 53 hormonal therapy 53 Randomized Study 53 TACE 53 taxane therapy 53 carotid endarterectomy 52 everolimus eluting stents 52 efficacy endpoint 52 preclinical efficacy 52 SYNTAX 52 HOPE TOO 52 newer atypical antipsychotics 52 pertuzumab 52 antiviral therapy 52 Taxus Stent 52 multicenter Phase III 52 HSCT 52 diuretic chlorthalidone 52 CTEPH 52 cardiovascular mortality 52 comorbidities 52 kidney transplant recipients 52 GFT# 52 co trimoxazole 52 polyarticular 52 immunomodulatory therapy 52 dyslipidaemia 52 heavily pretreated 52 vitro experiments 52 zotarolimus eluting stent 52 docetaxel chemotherapy 52 BRIM2 52 postoperative radiotherapy 52 montelukast 52 oral ibandronate 52 Intervention Effectiveness CATIE 52 antiepileptic drugs AEDs 52 HMG CoA reductase inhibitors 52 inhaled nitric oxide 52 rosiglitazone Avandia 52 Women Ischemia Syndrome 52 recurrent malignant glioma 52 HORIZONS AMI 52 STICH trial 52 dietary questionnaires 52 ascending dose 52 Dacogen injection 52 PROCRIT therapy 52 beta carotene supplements 52 salmeterol fluticasone 52 pharmacological therapies 52 azacitidine 52 stenting 52 CLARITY study 52 metastatic renal cell carcinoma 52 cetuximab 52 CTAP# Capsules 52 bolus dose 52 vandetanib 52 antiarrhythmic drug 52 secretin 52 Atacand 52 Intervention Trial 52 ginkgo biloba extract 52 basal bolus regimen 52 peginterferon alfa 2b 52 tamoxifen 52 GRAVITAS trial 52 locoregional recurrence 52 antithrombotics 52 genotypic resistance 52 solifenacin 52 nomograms 52 Pharmacokinetic 52 pomalidomide 52 TMC# C# 52 MMP inhibitors 52 coinfected patients 52 transurethral resection 52 Combination therapy 52 periprocedural MI 52 exploratory endpoints 52 hypertensives 52 cholinesterase inhibitors 52 ritonavir boosted 52 antithrombotic 52 candesartan cilexetil 52 enzastaurin 52 liver metastases 52 anakinra 52 anticonvulsant drugs 52 treatment regimens 52 intravenous dosing 52 patients undergoing CABG 52 risperidone Risperdal 52 Systematic reviews 52 cardiotoxicity 52 postoperative complications 52 Val MARC 52 reinfarction 52 tolerability profiles 52 PPIs 52 bisphosphonate therapy 52 tamsulosin 52 imatinib therapy 52 perinatal outcomes 52 virologically 52 EFAPROXYN 52 RECORD1 52 maximally tolerated dose 52 lung resection 52 sipuleucel T 52 WHI 52 CABG 52 antiretroviral therapy 52 anticoagulation therapy 52 oral antidiabetic agents 52 alteplase 52 dexmedetomidine 52 Multicenter 52 blinded placebo controlled 52 eplerenone 52 anticoagulation 52 IV NSCLC 52 ENGAGE AF TIMI 52 XL# SAR# 52 COPD exacerbations 52 nonvertebral fractures 52 unfractionated heparin UFH 52 pCR 52 TAXUS Stent 52 non inferiority 52 inhaled anticholinergics 52 subtrochanteric 52 evaluable patients 52 clinical endpoints 52 Neoadjuvant 52 aprotinin 52 velafermin 52 virologic failure 52 virologic 52 ENDEAVOR 52 multicenter randomized placebo controlled 52 generalisability 52 platelet inhibition 52 atherogenic dyslipidemia 52 Multiethnic Study 52 PFO closure 52 multicenter multinational 52 Amrubicin 52 neoadjuvant therapy 52 androgen ablation 52 ERCP 52 iPrEx 52 cytoreductive surgery 52 ginkgo extract 52 glargine 52 oral Hycamtin 52 colorectal neoplasia 52 Winkelmayer 52 Evaluation WISE 52 dabigatran 52 dacarbazine chemotherapy 52 AVADO 52 galiximab 52 unblinding 52 tecarfarin 52 irbesartan 52 ACTIVE W 52 virological response 52 INTERHEART 52 zinc supplementation 52 XEPLION R 52 Hepatocellular Carcinoma HCC 52 aromatase inhibitor therapy 52 BR.# 52 AEGR 52 febuxostat 52 EUS FNA 52 Dabigatran 52 Swedish Mammography Cohort 52 Elocalcitol 52 HCV infected 52 spinal manipulation 52 Zavesca R 52 prasugrel Effient 52 ROCKET AF 52 PROSTVAC ® 52 tumor histology 52 pharmacokinetic PK 52 Thrombolysis 52 vertebral fracture 52 cerebrovascular events 52 solid organ transplantation 52 randomized Phase 52 Efficacy 52 authors conclude 52 multivessel disease 52 pharmacodynamics PD 52 ACCORD 52 surrogate endpoint 52 cardioprotective effects 52 PREVENT IV 52 Framingham Offspring Study 52 blind randomized controlled 52 invasive bladder 52 infliximab 52 AZILECT R 52 anticoagulant therapy 52 aripiprazole 52 phase 2a 52 ENDEAVOR II 52 QTc prolongation 52 non selective NSAIDs 52 Phase 2b 52 antidepressant efficacy 52 CRLX# 52 Long Lesion 52 intravenous cyclophosphamide 52 menopausal hormone therapy 52 AVANDIA 52 iPrEx study 52 BRAF inhibitor 52 prazosin 52 epidemiological 52 HNSCC 52 lipid lowering therapies 52 warfarin 52 antiandrogens 52 probiotic supplementation 52 bivalirudin 52 MICARDIS ® 52 everolimus eluting stent 52 acute ischemic stroke 51 Phase III VISTA 51 adjunctive 51 Screening Trial 51 Lipid Lowering Treatment 51 pharmacodynamics 51 doxorubicin docetaxel 51 pharmacokinetic pharmacodynamic 51 lanthanum carbonate 51 DU #b 51 LEXIVA r 51 Coronary Artery Bypass Graft 51 dasatinib 51 lymph node involvement 51 HyQ 51 label multicenter Phase 51 interferon ribavirin 51 virologic responses 51 pharmacologic intervention 51 sulphonylureas 51 adecatumumab 51 5-FU/LV 51 pancreatic neuroendocrine tumors 51 NEVO RES 51 visilizumab 51 INTERCEPT platelets 51 carotid artery stenting CAS 51 mTOR inhibitors 51 antiangiogenic agents 51 blind placebo controlled 51 DMARD therapy 51 conditional logistic regression 51 TMC# r 51 NSAID 51 Novartis Zometa 51 myocardial infarctions MIs 51 Kantarjian 51 DMIST 51 routine episiotomy 51 FOSRENOL ® 51 RSD# oral 51 Cochrane Database 51 lenalidomide dexamethasone 51 HAART 51 thrombolysis 51 endometrial hyperplasia 51 composite endpoint 51 low dose cytarabine 51 cardiac toxicity 51 TriLipix 51 beam radiotherapy 51 Prospective Randomized Trial 51 pregabalin 51 oncological outcomes 51 MTWA testing 51 abiraterone 51 boosted protease inhibitor 51 LMWH 51 hepatectomy 51 duplex ultrasonography 51 pharmacological treatments 51 rALLy trial 51 MIRCERA 51 Celecoxib 51 goserelin 51 Bivalirudin 51 parathyroidectomy 51 FASLODEX 51 sorafenib 51 Arch Surg 51 TYGACIL 51 eribulin mesylate 51 aspirin clopidogrel 51 clinical 51 bicifadine 51 venous thromboembolic disease 51 prognostic variables 51 Randomised controlled trials 51 atherosclerotic renal artery stenosis 51 intraperitoneal chemotherapy 51 gefitinib 51 mg administered orally 51 SCIg 51 ruboxistaurin 51 PICSO ® 51 pharmacokinetic interaction 51 Taxotere ® 51 PSN# [002] 51 Pegylated Interferon 51 angiographic 51 OPCAB 51 CIMZIA ™ 51 prescribed opioids 51 plain radiographs 51 nelfinavir 51 pemetrexed 51 biochemical recurrence 51 antiepileptic drug 51 AVOREN 51 histologically proven 51 TDF FTC 51 NLX P# 51 NRTIs 51 atherothrombotic disease 51 reach statistical significance 51 Femara letrozole 51 hepatotoxicity 51 metabolic parameters 51 tirofiban 51 CURRENT OASIS 7 51 ONGLYZA 51 stratifying patients 51 cART 51 logistic regression analysis 51 immunohistochemical staining 51 Sunitinib 51 randomized Phase 2b 51 trastuzumab Herceptin ® 51 optimal dosing 51 pulmonary toxicity 51 raltegravir 51 COMFORT II 51 dronedarone 51 antidepressant therapy 51 CoFactor